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Background: Few studies of patients with CF have looked at the association between patient reported Health-Related Quality of Life (HRQoL)
and anxiety and depression. This study investigated whether CF patients with symptoms of anxiety or depression reported lower Health-Related
Quality of Life (HRQoL) scores.
Methods: 57 adult CF patients completed the Hospital Anxiety and Depression Scale (HADS) and the Cystic Fibrosis Questionnaire, a CF-specific
measure of HRQoL. Analyses of variance with lung function as a covariate were used to investigate differences in HRQoL between groups of
patients with and without symptoms of anxiety and depression.
Results:Mean age was 26.7 years (SD 8.1), mean FEV1 %predicted was 65.09 (SD 22.18). Anxiety and depression scores were low and similar to
normative scores. After controlling for lung function, patients with symptoms of anxiety reported lower on vitality, emotional functioning, social,
treatment burden, health perceptions and respiratory symptoms. Those with depressive symptoms reported lower HRQoL scores for emotional
functioning, eating disturbances and body image.
Conclusions: Preliminary evidence was found of the role of anxiety and depression in different areas of quality of life in CF, which may help in the
development of appropriate medical and psychosocial treatment programs.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Health-related quality of life; Anxiety; Depression1. Introduction
Health-related quality of life (HRQoL) has aroused substantial
interest in psychological and medical research about Cystic
Fibrosis (CF). It is a multidimensional psychological construct
that encompasses physical, psychological, social and functional
areas of life and the impact of health and illness on these.
Several studies have investigated psychosocial, demographic
and/or clinical factors on CF patients' perception of their HRQoL
[1–5]. Important CF-specific measures of HRQoL have been
developed in different languages [6–9]. Recent reviews have
discussedHRQoL as an outcomemeasure in clinical trials [10,11],⁎ Corresponding author. University Hospital Leuven 49, Herestraat, 3000
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doi:10.1016/j.jcf.2008.05.010and its association with antibiotic therapies [12] and lung
transplantation [13]. Many factors relate to aspects of HRQoL,
including coping, medical variables and compliance; but,
importantly, medical indicators of disease severity (e.g. lung
function, bodymass index and pulmonary exacerbations) are only
modestly related to HRQoL scores [5,3].
Little is known about the relationship between anxiety or
depression and HRQoL in CF. Studies have shown that adults
with CF report relatively healthy psychological functioning
[14,15]. In contrast, Riekert et al. [4] found depressive symp-
toms to be prevalent among adults with CF and associated with
poorer HRQoL even after controlling for lung function.
The present study was conducted to investigate further the
relationship between HRQoL and anxiety and depression, taking
into account lung function. Patients with stable disease were
screened for anxiety and depression using the Hospital Anxiety
and Depression Scale (HADS) [16] with a view to examiningd by Elsevier B.V. All rights reserved.
Table 1
Patient characteristics
Male–Female 29–28
Mean age (SD) 26.79 (8.15)
Lung function FEV1 %predicted 65.09 (22.18)
Table 3
Univariate analysis of variance with mean CFQ14+ domains scores as dependent
variables and anxiety and depression as independent variables, controlling for
lung function
CFQ-14+ domain Anxiety Depression
Normal Normal
Borderline/clinical Borderline/clinical
Physical functioning 79.14 (6.41) 72.46 (4.26)
65.62 (6.20) F=2.68,
p=0.10
72.29 (9.40) F=.000,
p=0.98
Role 71.61 (6.11) 70.76 (4.06)
61.84 (5.91) F=1.54,
p=0.22
62.68 (8.96) F=.58,
p=0.45
Vitality 63.69 (5.25) 58.41 (3.49)
47.96 (5.08) F=5.40,
p=0.02
53.24 (7.71) F=.33,
p=0.57
Emotional functioning 62.43 (4.81) 69.53 (3.19)
48.13 (4.65) F=5.34,
p=0.02
41.02 (7.05) F=11.81,
p=0.001
Social 68.77 (4.59) 65.11 (3.05)
56.10 (4.44) F=4.57,
p=0.03
59.76 (6.74) F=.45,
p=0.50
Body image 65.71 (6.08) 81.68 (4.04)
61.60 (5.88) F=.27,
p=0.60
45.63 (8.92) F=11.79,
p=0.001
Eating disturbances 77.68 (6.17) 88.78 (4.10)
75.09 (5.97) F=.11,
p=0.75
64.01 (9.05) F=5.41,
p=0.02
Treatment burden 58.02 (4.98) 53.39 (3.31)
43.17 (4.82) F=5.37,
p=0.02
47.79 (7.31) F=.42,
p=0.51
Health perceptions 54.06 (6.38) 46.85 (4.24)
29.40 (6.17) F=8.99,
p=0.004
36.61 (9.37) F=.86,
p=0.36
Weight 75.22 (8.80) 77.98 (5.85)
70.64 (8.51) F=.16,
p=0.68
67.88 (12.92) F=.44,
p=0.51
Respiratory symptoms 76.54 (4.80) 68.02 (3.19)
58.77 (4.65) F=8.22,
p=0.006
67.29 (7.05) F=.008,
p=093
Digestive symptoms 78.36 (5.38) 80.87 (3.57)
75.40 (5.20) F=.83,
p=0.67
72.89 (7.89) F=.74,
p=0.39
Mean scores evaluated at lung function=65.09.
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depressed reported a lower HRQoL.
2. Method
2.1. Study design and subjects
This cross-sectional study recruited patients consecutively
attending the Adult CF Centre at the University Hospital
Leuven between September 2006 and September 2007. Patients
whose disease was stable were asked to complete two ques-
tionnaires during an outpatient clinic visit as part of their annual
review. Fifty seven patients (67% of the adult clinic) completed
the questionnaires. Table 1 shows patient characteristics. Two
patients were evaluated for lung transplantation at the time
of this study. None of the patients declined to complete the
questionnaires, but patients experiencing a CF exacerbation or
complication, or admitted for treatment with IVantibiotics, were
excluded.
2.2. Measures
2.2.1. HRQoL
HRQoL was measured using a Dutch translation of the Teen/
Adult version of the CF Questionnaire (CFQ-14+) [17]. This
consists of 44 items across 12 scales (Table 2). The CFQ-14+ has
good reliability with Cronbach alpha 0.67 to 0.94. Response
choices generally included ratings of frequency and difficulty on
a 4-point scale (1= ‘always’ to 4= ‘never’; 1= ‘a lot of difficulty’
to 4= ‘no difficulty’) or true/false responses (1= ‘very true’ to
4= ‘very false’). Scores were standardized on a 0- to 100-point
scale, with higher scores representing better quality of life.
2.2.2. Anxiety and depression
Anxiety and depression were assessed using the Hospital
Anxiety and Depression Scale (HADS) [16]. This screeningTable 2
CFQ-teen/adult scales (CFQ-14+)
CFQ-14+ dimensions No. items Sample items
Physical functioning 8 Walking as fast as others
Role 2 How often were you absent f
Vitality 4 You felt tired
Emotional functioning 5 You felt worried
Social 5 I get together with my friends
Body image 3 I think I am too thin
Eating disturbances 3 I have to force myself to eat
Treatment burden 2 Compared to 3 months ago, h
Health perceptions 3 I feel healthy
Weight 1 Have you had trouble gaining
Respiratory symptoms 6 Have you had trouble breathi
Digestive symptoms 2 Have you had abdominal paininstrument consists of seven items that contribute to an anxiety
score and seven for a depression score, each on a four-point
Likert scale (0–3) with high scores indicating more symptoms.rom school/work during the last 2 weeks because of your illness or treatments?
a lot
ow much time do you currently spend on your treatment?
weight?
ng?
?
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overall score of 0–7 indicates no reason to suspect anxiety or
depression; a score of 8–10 indicates possible anxiety or de-
pression and a score higher than 11 indicates the possibility of a
clinical anxiety/depression disorder. Correlation between the
anxiety and depression scales is 0.63, pb0.001. For this study,
patients scoring 8 or above were allocated to the borderline/
clinical anxious or depressed group.
3. Results
3.1. HRQoL lung function
Lower FEV1 %predicted scores were associated with lower
scores on physical functioning and a worse perception of gen-
eral health (Pearson correlation r=0.27 and 0.38 respectively,
pb0.05).
3.2. Hads
The mean scores on the HADS were 5.6 (SD 3.9) for anxiety
and 3.5 (SD 3.6) for depression. These scores were similar to
reference values from a healthy population [18]: anxiety 5.1
(SD 3.6) and depression 3.4 (SD 3.3). For anxiety, 39 patients
(70%) scored in the normal category and 18 (30%) in the
borderline/clinical category. For depression, 48 (87%) and 9
(13%) patients scored in the normal and borderline/clinical
categories, respectively. No differences were found in FEV1 %
predicted between the normal versus borderline/clinical anxious
or depressed groups.
3.3. HRQoL in relation to anxiety and depression
Analyses of variance were conductedwith CFQ-14+ domains
as dependent variables and anxiety and depression as indepen-
dent variables (Table 3). After controlling for lung function,
those patients who reported symptoms of anxiety had poorer
HRQoL scores for vitality, emotional functioning, social, treat-
ment burden, health perceptions and respiratory symptoms.
Those with depressive symptoms reported lower HRQoL scores
for emotional functioning, eating disturbances and body image.
4. Discussion
The results relating CFQ-14+ domains to lung function were
in line with those reported by others [4,7,17,19], with lower
FEV1 %predicted scores correlating with lower scores in the
domains physical functioning and health perceptions.
As with other studies on anxiety and depression in CF [14],
but contrary to the results of Riekert et al. [4], patients in our
study did not report significantly more symptoms of anxiety and
depression than their non-CF peers. After controlling for lung
function, patients with borderline/clinical anxiety and/or de-
pression scored significantly lower on aspects of HRQoL.
Patients with symptoms of anxiety reported lower on vitality,
emotional functioning, social treatment burden, health percep-
tions and respiratory symptoms. Patients with symptoms ofdepression reported lower on emotional functioning, eating
disturbances and body image. Both anxiety and depression have
been described in other chronic conditions as risk factors for
poor adherence to therapy, increased mortality and increased
health care utilization [20–22]. Screening for anxiety and de-
pression may help in the development of treatment programs to
preventing these risk factors.
The results do not, of course, specify the direction of the
relationship between anxiety and depression and HRQoL.
Anxiety may lead a patient to report worse aspects of HRQoL,
or the patient's perception of a poor HRQoLmight be the cause of
anxiety, perhaps leading in turn to non-compliance and
deterioration of health. This issue is particularly important when
using HRQoL as an outcome measure in trials. In trials one needs
to be certain that the outcome measure actually measures the
underlying concepts of HRQoL and not anxiety or depression or
other variables.
Even though HRQoL was measured using a CF-specific
scale, it is possible that the observed relationship between
anxiety and depression and certain domains of HRQoL can also
apply in non-CF peers and is not specifically linked with CF.
The HADS is an instrument that reliably screens or rules out
anxiety and depression but is not a diagnostic tool and may not
be interpreted as such [20,21,23]. Despite this limitation—
which warrants further study—the HADS is quick and easy to
administer, and its items do not include reference to physical
symptoms. Results should be considered alongside clinical
observations and further assessments carried out if needed.
5. Conclusion
This study provides preliminary evidence of a relationship
between anxiety and depression and HRQoL in patients with
CF. Screening for anxiety and depression may help in the
development of appropriate medical and psychosocial treatment
programs and in improving some patients' perception of their
HRQoL.
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